Ozempic before-and-after videos: what the weight loss science actually shows

What's this video probably claiming?

Based on the hashtags and caption, this is almost certainly a before-and-after transformation video tied to semaglutide use. The word "surreal" signals that the creator is expressing genuine surprise at their own results, which is a common framing in Brazilian GLP-1 content. The hashtags reference both "ozempic" and "semaglutida" directly, alongside weight loss tags like "emagrecimento" and "perdadepeso." The implied claim is straightforward: semaglutide produced dramatic, fast, and visually striking fat loss. That may well be true for this individual. The problem is that before-and-after videos compress months of complex metabolic change into a single emotional frame, stripping out context about diet, dosing, side effects, and what happens when the drug stops. Without the transcript, we can't confirm exact claims, but the visual format itself is the message, and that message almost always overpromises.

What does the science actually show?

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4 mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. That is genuinely impressive. But 68 weeks is over a year, and those results required a caloric deficit alongside the drug. The STEP 4 trial (Rubino et al., 2021, JAMA) is the one most social media posts ignore: participants who discontinued semaglutide regained roughly two-thirds of their lost weight within a year. A 2022 analysis in Obesity Reviews by Greenway reinforced that GLP-1 drugs suppress appetite primarily through hypothalamic signaling, not permanent metabolic restructuring. The drug works while you take it. When you stop, the biology reasserts itself. Dramatic before-and-afters rarely mention which phase of that cycle the creator is currently in.

Where does the social media noise diverge from clinical reality?

The divergence is substantial and follows predictable patterns. First, transformation videos almost always capture peak results, typically at the 6-12 month mark, before potential plateaus or regain. Second, Brazilian social media in particular conflates Ozempic (semaglutide 0.5-1 mg, approved for type 2 diabetes) with Wegovy (semaglutide 2.4 mg, approved for obesity). These are different approved doses for different indications, and treating them as interchangeable is clinically inaccurate. Third, side effect profiles get buried. The STEP trials reported nausea in roughly 44% of participants, vomiting in 24%, and diarrhea in 30% at therapeutic doses. You do not see that in a caption that says "surreal." Fourth, access and cost are invisible in these videos. Semaglutide brand-name pricing in Brazil and globally remains a significant barrier, and compounded versions carry their own regulatory and safety questions that no hashtag communicates.

What should you actually know?

Semaglutide is one of the most well-studied weight loss interventions in modern medicine. The clinical evidence is not in dispute. What is in dispute is how social media translates that evidence into personal narratives that function more like advertisements than information. If you are considering GLP-1 therapy, the relevant questions are not whether someone looks different in a video but whether you have cardiovascular contraindications (the drug carries a boxed warning about thyroid C-cell tumors in rodent studies, and is contraindicated with personal or family history of medullary thyroid carcinoma), how you will manage the drug long-term given its dependency profile, and whether the version you are accessing, brand name or compounded, is what your prescriber actually intended. A telehealth evaluation is not a formality. It is the mechanism through which those questions get answered.